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Abstract
Introduction: Mechanisms underlying low-penetrance, common, non-protein coding variants in breast cancer risk
loci are largely undefined. We showed previously that the non-protein coding mammary carcinoma susceptibility
locus Mcs5a/MCS5A modulates breast cancer risk in rats and women. The Mcs5a allele from the Wistar-Kyoto (WKy)
rat strain consists of two genetically interacting elements that have to be present on the same chromosome to
confer mammary carcinoma resistance. We also found that the two interacting elements of the resistant allele are
required for the downregulation of transcript levels of the Fbxo10 gene specifically in T-cells. Here we describe
mechanisms through which Mcs5a may reduce mammary carcinoma susceptibility.
Methods: We performed mammary carcinoma multiplicity studies with three mammary carcinoma-inducing
treatments, namely 7,12-dimethylbenz(a)anthracene (DMBA) and N-nitroso-N-methylurea (NMU) carcinogenesis, and
mammary ductal infusion of retrovirus expressing the activated HER2/neu oncogene. We used mammary gland and
bone marrow transplantation assays to assess the target tissue of Mcs5a activity. We used immunophenotyping
assays on well-defined congenic rat lines carrying susceptible and resistant Mcs5a alleles to identify changes in T-
cell homeostasis and function associated with resistance.
Results: We show that Mcs5a acts beyond the initial step of mammary epithelial cell transformation, during early
cancer progression. We show that Mcs5a controls susceptibility in a non-mammary cell-autonomous manner
through the immune system. The resistant Mcs5a allele was found to be associated with an overabundance of gd
T-cell receptor (TCR)+ T-cells as well as a CD62L (L-selectin)-high population of all T-cell classes. In contrast to in
mammary carcinoma, gdTCR+ T-cells are the predominant T-cell type in the mammary gland and were found to
be overabundant in the mammary epithelium of Mcs5a resistant congenic rats. Most of them simultaneously
expressed the CD4, CD8, and CD161a markers. In cultured T-cells of Mcs5a resistant congenic rats we found
increased mitogen-induced proliferation and production of Th1 cytokines IFNg, IL-2, and Tumor Necrosis Factor
(TNF), but not Th2 cytokines IL-4 and IL-6, or Th17 cytokine IL-17 when compared with susceptible control rats.
Conclusions: These data support a hypothesis that Mcs5a displays a non-mammary cell-autonomous mechanism
of action to modulate breast cancer risk through the immune system. The resistant Mcs5a allele is associated with
alterations in T-cell homeostasis and functions, and overabundance of gδTCR+ T-cells in carcinogen-exposed
mammary epithelium.
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The genetic component of risk for most common forms
of breast cancer defines it as a complex trait consisting
of numerous susceptibility alleles and interactions. Thus
far, approximately 25 such alleles have been identified
by using genome-wide association studies and compara-
tive genetics [1-10]. A great majority of these alleles are
non-protein-coding and each is associated with a low
relative risk. Currently, a major open question regarding
breast cancer susceptibility alleles is defining their func-
tion and risk-controlling mechanisms. Such insight will
allow the use of discovered alleles to go beyond prog-
nosis and toward the development of novel anticancer
strategies and agents.
We identified the mammary carcinoma susceptibility-
5a (Mcs5a) locus by using a comparative genetics
approach and have shown that it controls breast cancer
risk in both rats and women [5]. The Mcs5 quantitative
trait locus was initially identified by linkage analysis in
the backcross progeny of the mammary carcinoma sus-
ceptible Wistar-Furth (WF) rat strain and the resistant
Wistar-Kyoto (WKy) rat strain [11]. Genetic fine-map-
ping using congenic recombinant rat lines resulted in
the identification of three mammary carcinoma risk loci,
one of which was Mcs5a [12,13]. The resistant allele of
Mcs5a, when introgressed into the susceptible genetic
background, is associated with an approximately 50%
reduction in mammary carcinoma multiplicity. Mcs5a
consists of two non-protein-coding synthetically inter-
acting elements (Mcs5a1 and Mcs5a2)t h a tm u s tb e
located on the same chromosome to elicit the resistance
phenotype. Previously, we showed that the expression
levels of genes located within 1 Mb surrounding this
locus, including Fbxo10, Frmpd1,a n dTomm5 (partially)
overlapping with the locus, were not differentially
expressed in the mammary gland of susceptible con-
genic control and Mcs5a-resistant congenic rats. We
showed that the non-protein-coding synthetically inter-
acting elements of the resistant allele are required for
the downregulation of transcript levels of the E3 ubiqui-
tin ligase gene Fbxo10 in the thymus. The differential
Fbxo10 expression between susceptible congenic control
and Mcs5a-resistant congenic animals is detectable in
immature, naïve, and activated T cells and not in ovary,
brain [5], or other cells of the immune system [14]. The
transcript levels of Tomm5 and Frmpd1 in immune tis-
sues are not associated with the presence of the inter-
acting genetic elements of the resistant allele [14]. The
genetic interaction is facilitated by a human-rat con-
served higher-order chromatin-folding structure [14]. In
a case-control association study, a non-protein-coding
breast cancer risk-associated allele was identified in each
orthologous human locus (MCS5A1 and MCS5A2)t o
resolutions of approximately 5.7 Kb and approximately
26.1 Kb, respectively [5]. We recently found that the
variants associated with lower breast cancer risk in the
human orthologous loci MCS5A1 and MCS5A2 are
located at both sides of the looped structure and func-
tionally interact to downregulate transcriptional activity
of reporter constructs transfected into a human T-lym-
phocytic cell line [14]. MCS5A2 (marked by the single-
nucleotide polymorphism rs2182317) was recently veri-
fied as a breast cancer risk allele, modifying risk to both
estrogen receptor-positive and -negative breast cancers
[4].
We hypothesize that similar mechanisms underlie the
rat and human Mcs5a/MCS5A breast cancer susceptibil-
ity alleles given that these reside in orthologous genomic
intervals, show similar higher-order chromatin structure,
and control highly similar complex traits. Congenic rat
lines provide a unique opportunity to investigate the
activities of this locus on the level of specific cell types
in a mammalian model organism. Mcs5a is shown here
to act on mammary carcinoma multiplicity beyond the
initial stage of mammary epithelial cell transformation,
in a non-mammary cell-autonomous manner through
the immune system, and to alter homeostasis and func-
tion of specific T-cell populations.
Materials and methods
Animals
The congenic rat lines were established and maintained
in a facility approved by the Association for Assessment
and Accreditation of Laboratory Animal Care, as pre-
viously published [13]. All animal protocols were
approved by the University of Wisconsin Medical School
Animal Care and Use Committee. Congenics are defined
as genetic lines that were developed on a WF (suscepti-
ble) genetic background and that carry the selected
WKy (resistant) Mcs5a alleles. Resistant congenic lines
(’Mcs5a’; lines WW and O) with decreased susceptibility
phenotypes are WKy-homozygous at the entire Mcs5a
locus [5]. The susceptible congenic control line (’susc.’;
line WF.WKy) derived from the O congenic line is WF-
homozygous at Mcs5a and all other identified Mcs loci.
Other susceptible congenic lines are WKy-homozygous
at Mcs5a1 (’Mcs5a1’; line B3) and WKy-homozygous at
Mcs5a2 (’Mcs5a2’; line LL) [5].
Carcinogenesis
Female rats (age of 50 to 55 days) were orally gavaged
with 7,12-dimethylbenz(a)anthracene (DMBA) at 65 mg/
kg of body weight or were injected intraperitonially with
N-nitroso-N-methylurea (NMU) at 50 mg/kg of body
weight or were subjected to mammary ductal infusion
of replication-defective retrovirus expressing the acti-
vated HER2/neu oncogene (HER2/neu) at a concentra-
tion of 5 × 10
5 to 1 × 10
6 colony-forming units (CFU)
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female rats of 50 to 55 days of age were subjected to
HER2/neu infusion at 1 × 10
7 CFU/mL [16]. To obtain
multiplicities, mammary carcinomas of greater than 3 ×
3 mm were counted at 15, 17, and 8 weeks after DMBA,
NMU, or HER2/neu treatment, respectively, and ISCs
were determined by counting individual carcinomas in
whole-mounted abdominal mammary glands stained
with aluminum carmine at 16 days after treatment. Mul-
tiplicity data were statistically analyzed by using Mann-
Whitney non-parametric tests.
Mammary gland transplantation
Donor mammary glands with lymph nodes (LNs) excised
(both abdominal and adjacent inguinal glands) from 30-
to 35-day-old females were finely minced over ice and
divided into four equal volumes. One volume was trans-
planted onto the interscapular white fat pad of each 30-
to 35-day-old recipient (one donor per four recipients).
Three weeks after transplantation, all recipients were
treated with DMBA as described above. At 15 weeks
after DMBA, interscapular fat pads were examined for
carcinoma development. In addition, each fat pad was
whole-mounted and stained with aluminum carmine to
verify mammary gland establishment. As only 11 out of
213 rats developed multiple carcinomas in the transplant
s i t e s ,t h ed a t aw e r ea n a l y z e da sab i n a r yr e s p o n s eb y
logistic regression. The four transplant groups (donor to
recipient: susceptible to susceptible, S:S; susceptible to
resistant, S:R; resistant to susceptible, R:S; and resistant
to resistant, R:R) form a 2 × 2 factorial design with donor
and recipient genotypes as the main effects. Standard
logistic regression was applied to the binary response
data with two main effects and an interaction term.
Bone marrow transplantation
At 30 to 35 days of age, recipient rats were irradiated
twice with 400 (2 × 400) rads each time. The second
radiation dose was given 3 hours after the first dose.
Within 6 hours after irradiation, recipients were given 1
×1 0
6 bone marrow cells from 30- to 35-day-old donors
via tail vein injection. Recipients were treated with
DMBA 4 weeks after transplantation. At 15 weeks after
DMBA, mammary carcinomas of at least 3 × 3 mm
were counted. Transplanted donor alleles were quanti-
fied by using TaqMan allelic discrimination on recipient
whole-spleen genomic DNA. The quantities of trans-
planted donor alleles were estimated from a standard
curve approach that was anchored by incorporated dilu-
tions of WF- and WKy-homozygous DNA. The TaqMan
probes (Applied Biosytems, Foster City, CA, USA) were
designed to genotype a single-nucleotide polymorphism
at chr5:61,634,727 in v3.4 of the rat genome.
Flow cytometry
In all flow cytometry experiments, cells were stained
with fluorophore-conjugated antibodies against rat
CD3, CD4, CD8, CD62L, or gδTCR (BD Biosciences,
San Jose, CA, USA) or isotype controls in serum-con-
taining media or phosphate-buffered saline/Hepes. For
T-cell phenotyping, spleen or mammary inguinal LN
cells were obtained by squeezing the tissue through a
sterile mesh in a Petri dish containing RPMI medium.
The red blood cells were lysed by a brief hypotonic
shock. To obtain mammary ductal fragments, mam-
mary glands with LN excised (both abdominal and the
adjacent inguinal glands) from DMBA-treated (4 weeks
after treatment) and age-matched untreated females
were finely minced over ice. Each sample was exposed
to 10 mL of GIBCO Dulbecco’s modified Eagle’sm e d -
ium/F12 (DMEM/F12) (Invitrogen Corporation, Carls-
bad, CA, USA) containing 0.01 g/mL of type III
collagenase (Worthington Biochemical Corporation,
Lakewood, NJ, USA) for 2 hours at 37°C under gentle
rotation. DNAseI (Worthington Biochemical Corpora-
tion) was added to 0.2 μg/mL, and the samples were
incubated for 10 minutes under vigorous shaking. Fat
was removed from the pelleted cell fraction by pipet-
ting, and the pellet was washed once with DMEM/F12.
The pellet was dissolved in 5 mL of DMEM/F12 and
loaded on a pre-wetted 54- μm nylon filter to collect
the mammary ductal fragments. To monodispense the
ductal fragments, they were washed, trypsinized, and
passed through a 40- μm cell strainer. Frank mammary
carcinomas were dissected from female susceptible
congenic control rats at 15 weeks after DMBA. To
monodisperse frank mammary carcinomas, tissue was
scissor-minced finely over ice, collagenase-treated, and
trypsinized as described above.
After cell staining, 50,000 cells were acquired in a
BD LSR II flow cytometer (BD Biosciences). The sam-
ples were compensated using single-stained cells using
BD FACS-Diva software (BD Biosciences). T-cell sub-
populations (CD4
+,C D 8
+, gδTCR
+,a n dC D 1 6 1 a)
were gated and the mean fluorescence intensity (MFI)
of CD62L was calculated by using FlowJo software
(TreeStar Inc., Ashland, OR, USA). The CD62L
high
gate was set such that the MFI of the CD62L
high-
expressing cells was fivefold the MFI of the total cells.
For calculation of normalized MFI of CD62L, the MFI
of different T-cell subpopulations in each experiment
was normalized against the MFI of CD62L of CD4
+ T
cells in susceptible congenic control animals from
that experiment. Data were statistically analyzed by
using Mann-Whitney non-parametric tests. Hoechst
staining was used to gate live cells containing 2n-4n
DNA.
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Two million lymphocytes from spleen or inguinal mam-
mary LNs were stimulated with 1 μg/mL concanavalin
A (conA) (Calbiochem, now part of EMD Biosciences,
Inc., San Diego, CA, USA) and were cultured in 2 mL
of RPMI medium containing 10% fetal bovine serum for
24 hours at 37°C in a 95% air/5% CO2 atmosphere.
Unstimulated cells served as a control. The expression
levels of IL-2, IL-4, IL-6, IL-17, interferon-gamma
(IFNg), and tumor necrosis factor (TNF) cytokines in
the supernatants were measured by enzyme-linked
immunosorbent assay (ELISA). ELISA sets for rat IL-4,
IL-6, IFNg,a n dT N Fw e r eo b t a i n e df r o mB DB i o s -
ciences. ELISA sets for rat IL-17 and IL-2 were pur-
chased from eBioscience, Inc. (San Diego, CA, USA)
and R&D Systems, Inc. (Minneapolis, MN, USA),
respectively.
In vitro T-cell proliferation
Splenic lymphocytes were stained with 1 μMc a r b o x y -
fluorescein succinimidyl ester (CFSE) (Invitrogen Cor-
poration) for 8 minutes at 37°C and washed three
times using ice-cold RPMI medium containing 10%
fetal calf serum. Two million lymphocytes were stimu-
lated with 1 μg/mL conA and were cultured in 2 mL
of RPMI medium containing 10% fetal bovine serum
for 4 days at 37°C in a 95% air/5% CO2 atmosphere.
Unstimulated cells served as a control. Cells were
stained with fluorochrome-conjugated antibodies
against rat CD3, CD4, CD8, gδTCR, or isotype controls
and fixed in 1% formaldehyde. Cell proliferation was
m e a s u r e db yd y ed i l u t i o nb yu s i n gaB DL S RI If l o w
cytometer. Percentages of cells that showed a decrease
in CFSE fluorescence intensity were calculated by
using FlowJo software and were defined as daughter
cells in various T-cell subpopulations. In each experi-
ment, the percentage of daughter cells in different T-
cell subpopulations was normalized against the percen-
tage of CD4
+ daughter T cells in the susceptible con-
g e n i cc o n t r o lg r o u pf r o mt h a te x p e r i m e n t .
CD25 and CD134 expression and estimation of
intracellular reduced thiols and mitochondrial membrane
potential
Unstimulated cells and activated cells were stained with
fluorochrome-conjugated antibodies against rat CD3,
CD25, and CD134 or isotype controls and fixed in 1%
formaldehyde, and 20,000 cells were acquired in a BD
LSR II flow cytometer. Percentages of CD3
+ T cells that
expressed CD25 or CD134 were calculated by using
FlowJo software. To measure intracellular reduced
thiols, in cultured T cells, monochlorobimane (MCB)
(final concentration of 40 μM, 30 minutes at 37°C) was
loaded into cells. The cells were further stained with
fluorochrome-conjugated rat CD3 antibody and were
acquired on a flow cytometer. MCB fluorescence was
measured at wavelengths of 350 nm (excitation) and 450
nm (emission). Mean MCB fluorescence in T cells was
calculated by using FlowJo software. To measure mito-
chondrial membrane potential in cultured T cells, JC1
dye (final concentration of 2.5 μg/mL, 30 minutes at 37°
C) was loaded into cells. The cells were further stained
with fluorochrome-conjugated rat CD3 antibody and
were acquired on a flow cytometer. JC1 was excited by
using a 488-nm laser, and emission was measured at
wavelengths of 530 and 575 nm. The ratio of yellow to
green fluorescence in T cells was calculated by using
FlowJo software.
Results
Mcs5a acts during early mammary cancer progression
The rat Mcs5a l o c u sw a sf i n e - m a p p e da saD M B A -
induced mammary carcinoma multiplicity phenotype.
To rule out the possibility that Mcs5a affects the meta-
bolic activation of DMBA, mammary carcinomas were
induced by two additional treatments, namely carcino-
genesis using the directly alkylating agent NMU and
mammary ductal infusion of replication-defective ret-
rovirus expressing the activated HER2/neu oncogene
(HER2/neu) [15]. DMBA-, NMU-, and HER2/neu-
induced mammary carcinoma multiplicities were com-
pared between the susceptible congenic control line
and the Mcs5a-resistant congenic line. Resistance to
DMBA-, NMU-, and HER2/neu-induced mammary
carcinogenesis was found to be 55%, 42%, and 42%,
respectively (Figure 1a-c). Mcs5a conferred resistance
to mammary carcinoma development induced by all
three agents, suggesting that Mcs5a acts beyond the
stage of cancer initiation. This was further investigated
by assessing whether Mcs5a confers resistance to the
formation of rapidly developing mammary carcinomas,
termed ISCs [16]. Therefore, ISC multiplicity was
determined 16 days after HER2/neu infusion. Suscepti-
ble congenic control and Mcs5a-resistant congenic rats
did not differ in their average ISC multiplicity (Figure
1d). This result is compatible with a hypothesis that
Mcs5a acts through a mechanism during early mam-
mary cancer progression.
Mcs5a acts through a non-mammary cell-autonomous
mechanism
To functionally investigate whether Mcs5a acts via a
mammary cell-autonomous mechanism, a mammary
gland transplantation assay was conducted. Mammary
gland tissue from donor susceptible congenic control or
Mcs5a-resistant congenic animals was transplanted into
the interscapular white fat pads of recipient congenic
animals of the same or opposite Mcs5a genotype. For
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plantation efficiency and carcinoma development follow-
ing DMBA exposure were monitored (Table 1). There
was no difference in the mammary tissue transplantation
rate associated with donor and recipient or the interac-
tion between donor and recipient genotypes (Table 1),
ensuring that graft rejection was not a confounding vari-
able in these congenic lines. The rates of mammary car-
cinoma incidence at the transplant site were 52%, 31%,
45%, and 25% for transplant groups S:S, S:R, R:S, and R:
R, respectively (Figure 2a). Logistic regression analysis
revealed that recipient genotype (P = 0.04), but not
donor genotype (P = 0.65), was significantly associated
with transplant site carcinoma development (Table 1).
The interaction between donor and recipient genotype
was not significant (P = 0.96) for the dependent variable
mammary gland transplant carcinoma susceptibility
(Table 1). These data demonstrate that the mammary
carcinoma susceptibility phenotype mediated by Mcs5a
is not transferable by transplantation of the mammary
gland, indicating that Mcs5a does not act in a mammary
cell-autonomous manner.
Mcs5a acts within immune cells to mediate mammary
carcinoma susceptibility
The regulatory activity of the non-protein-coding Mcs5a
locus on the expression of genes located within 1 Mb
was found to manifest in the immune system and not in
Figure 1 Mcs5a acts beyond mammary epithelial cell transformation during early cancer progression. (a) 7,12-Dimethylbenz(a)anthracene
(DMBA)-induced mammary carcinoma multiplicities (susc., n = 27; Mcs5a, n = 49). (b) N-nitroso-N-methylurea (NMU)-induced mammary
carcinoma multiplicities (susc., n = 29; Mcs5a, n = 28). (c) Mammary carcinoma multiplicities induced by mammary ductal infusion of retrovirus
expressing the activated HER2/neu oncogene (HER2/neu) (susc., n = 15; Mcs5a, n = 15). (d) HER2/neu-induced in situ carcinoma multiplicities
(susc., n = 24; Mcs5a, n = 24). Values are expressed as average ± standard error of the mean. Significance (P < 0.05) is indicated by an asterisk.
Mcs5a, resistant congenic harboring the mammary carcinoma susceptibility locus 5a resistance allele; susc., susceptible congenic control.
Table 1 Mammary gland transplantation data and logistic regression analysis
MG transplantation data
a Logistic regression analysis
b
S:S S:R R:S R:R Total Independent Coefficient P value
Transplant MG present 31 72 22 88 213 MG transplantation efficiency Donor effect -0.3502 0.6449
Transplant MG absent 6 11 3 11 31 Recipient effect -0.4372 0.4423
Percentage of MG present 84% 87% 88% 89% 87% Donor × recipient 0.3389 0.7056
0 carcinomas 15 50 12 66 143
1 carcinoma 13 17 10 19 59 MG transplant carcinoma
susceptibility
Donor effect -0.2468 0.6588
2 carcinomas 3 4 0 3 10 Recipient effect -0.8855 0.0447
c
3 carcinomas 0 1 0 0 1 Donor × recipient 0.0307 0.9629
Percentage of MGs with 1 carcinoma 52% 31% 45% 25% 33%
aTransplant groups (donor/recipient): S:S, susceptible/susceptible; S:R, susceptible/resistant; R:S, resistant/susceptible; R:R, resistant/resistant.
bLogistic regression
was used to estimate the effect of donor and recipient and the interaction between donor and recipient for the dependent variables mammary gland (MG)
transplantation efficiency (outcome = histologically determined presence or absence of MG development at transplant site) and MG transplant carcinoma
susceptibility (outcome = tumor presence or absence at transplant site) in susceptible congenic control and Mcs5a-resistant congenic reciprocal (donor, recipient)
transplant groups.
cStatistically significant.
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components of the immune system mediate the activity
of Mcs5a in controlling the mammary carcinoma sus-
ceptibility phenotype. To evaluate this, a bone marrow
transplantation assay was carried out. Mcs5a-resistant
congenic and susceptible congenic control female recipi-
ents were irradiated to eliminate their bone marrow
progenitor cells and grafted with bone marrow cells
from either Mcs5a-resistant congenic or susceptible
congenic control donors yielding four transplant groups
(donor/recipient): S:S, S:R, R:S, and R:R. Graft levels of
the immune system were quantified by using a TaqMan
allelic discrimination assay on whole-spleen genomic
DNA, with dilutions of genomic DNA of the respective
homozygous Mcs5a genotypes as standards. At a dose of
2 × 400 rads, average replacement levels of greater than
50% were obtained in the S:R group in two out of four
trials. Only data from the two experiments yielding
greater than 50% of average replacement were included.
Average replacement levels of greater than 50% were
obtained in the R:S group in none of four trials and
therefore could not be included in the analysis. A higher
dose (2 × 500 rads) to get potentially higher levels of
replacement resulted in cell killing in mammary gland
and ovarian tissues at levels that preclude the develop-
ment of mammary carcinomas for quantitative analysis
(data not shown). At the dose of 2 × 400 rads, the
average (± standard error of the mean) DMBA-induced
mammary carcinoma multiplici t yf o rt h er e s i s t a n tc o n -
trol group R:R (1.4 ± 0.3) was reduced by approximately
64% as compared with the susceptible control group S:S
(3.9 ± 0.4) (Figure 2b). The S:R transplant group yielded
an intermediate average number of mammary carcino-
mas (2.2 ± 0.4). These data suggest that Mcs5a acts
through components of the immune system to modulate
mammary carcinoma susceptibility.
Mcs5a modulates T-cell homeostasis and functions
We used the congenic rat lines to identify the target cell
type in the immune system for the gene-regulatory
activity of Mcs5a. The transcript level downregulation of
Fbxo10 in thymocytes, primary T cells, cultured unsti-
mulated T cells, and cultured conA-stimulated T cells
appeared to be associated with the presence of the
synthetically interacting genetic elements of the resistant
Mcs5a allele [14]. Using immunophenotyping assays on
T cells from spleen, inguinal mammary LN, and mam-
mary epithelium from Mcs5a-resistant congenic (Mcs5a)
and susceptible congenic rat lines (susc., Mcs5a1 and
Mcs5a2), we investigated whether functional characteris-
tics and phenotypes of various T-cell subpopulations are
also associated with the Mcs5a-resistant allele. If a cer-
tain phenotype is present in the Mcs5a-resistant con-
genic animals only and not in the susceptible congenic
Figure 2 Mcs5a acts in a non-mammary cell-autonomous fashion through cells of the immune system. (a) Percentage of transplant sites
with one or more carcinomas in the mammary gland transplantation assay. Transplant groups are indicated as donor/recipient. Logistic
regression analysis indicated a significant effect (P = 0.04) of the recipient on transplant site carcinoma incidence (Table 1). The animals in
susceptible/susceptible (S:S), susceptible/resistant (S:R), resistant/susceptible (R:S), and resistant/resistant (R:R) transplant groups numbered 31, 72,
22, and 88, respectively. (b) 7,12-Dimethylbenz(a)anthracene-induced mammary carcinoma multiplicities (expressed as average ± standard error
of the mean) after bone marrow transplantation. Transplant groups are indicated as donor/recipient. Transplant group S:R (carrying an average
immune system replacement of 53%; n = 16) displays a mammary carcinoma multiplicity intermediate to transplant groups R:R (n = 17) and S:S
(n = 12). Mcs5a, mammary carcinoma susceptibility locus 5a.
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with the Mcs5a-resistant allele. The percentages of CD4
+ T cells and CD8
+ T cells in the CD3
+ T-cell popula-
tion were found to be similar in spleens from resistant
and susceptible congenic rat lines (Figure 3a, b). How-
ever, the proportion of gδTCR
+ T cells among the CD3
+
T cells was significantly higher (P < 0.0001) for Mcs5a-
resistant congenic rats (Figure 3c).
The expression of L-selectin (CD62L) was signifi-
cantly higher on CD4
+ (P = 0.0001), CD8
+ (P =
0.0036), and gδTCR
+ (P = 0.0023) T cells from the
spleen of the Mcs5a-resistant congenic rats (Figure 4a,
b). This observation can be attributed to higher levels
of CD62L
high-expressing cells in all T-cell subpopula-
tions from Mcs5a-resistant congenic rats compared
with the susceptible congenic rat lines (Figure 4c-e).
The role of L-selectin in the homing of T cells to sec-
ondary lymphoid organs and sites of inflammation in
extralymphoid organs has been well established [17].
Therefore, the composition of the T-cell compartment
of the mammary epithelium of untreated and DMBA-
treated rats was examined. The mammary epithelium
of untreated Mcs5a-resistant congenic rats as com-
pared with susceptible congenic control rats had equal
percentages of CD3
+ T cells (Figure 5a), of which CD4
+ and CD8
+ T cells were equal as well, but gδTCR
+ T
cells showed a strong trend (P =0 . 0 5 5 )t o w a r do v e r a -
bundance (Figure 5a). After DMBA treatment, CD3
+
T-cell abundance in the mammary epithelium
increased in both susceptible congenic control (P =
0.031) and Mcs5a-resistant congenic (P = 0.007) rats
as compared with the untreated mammary epithelium
(Figure 5a). This increase is attributable to the CD8
+
or gδTCR
+ T cells or both and not attributable to the
CD4
+ T cells. Subsequently, DMBA-treated Mcs5a-
resistant congenic rats were found to have significantly
higher percentages of CD3
+ (P = 0.016), CD8
+ (P =
0.018), and/or gδTCR
+ (P < 0.001) T cells and a signifi-
cantly lower percentage of CD4
+ Tc e l l s( P = 0.019) as
compared with susceptible congenic control rats (Fig-
ure 5a). Next, we examined the same classes of T cells
within DMBA-induced mammary carcinomas (Figure
5b). We found an overabundance (P = 0.048) of CD3
+
T cells in the mammary carcinomas from the Mcs5a-
resistant congenic rats compared with the susceptible
congenic control rats. Interestingly, these CD3
+ T cells
consisted mainly of CD4
+ and CD8
+ abTCR
+ Tc e l l s ,
and gδTCR
+ T cells were a minor population (Figure
5b). The mammary carcinoma T cells do not appear to
be activated, since they did not produce IFNg (data not
shown).
As a result of the observation that gδTCR
+ Tc e l l si n
the normal mammary epithelium seem to also express
CD8 (Figure 5a), we characterized the mammary gland
gδTCR
+ T-cell population in comparison with the sple-
nic gδTCR
+ T-cell population (Figure 5c). In contrast to
splenic gδTCR
+ T cells, most of the mammary gland
gδTCR
+ T cells expressed the CD4, CD8, and CD161a
markers simultaneously (Figure 5c).
To evaluate whether Mcs5a affects T-cell functions,
cytokine and proliferation assays were carried out.
ConA-activated splenic T cells from Mcs5a-resistant
congenic rats produced significantly higher levels of
Th1 cytokines IL-2 (P = 0.0001), IFNg (P = 0.0033), and
TNF (P = 0.0045) as compared with T cells from sus-
ceptible congenic control rats (Figure 6a). These differ-
ences were found to be more pronounced when
analyzing the conA-induced Th1 cytokine production of
Figure 3 Mcs5a modulates gδTCR
+ T-cell homeostasis.P e r c e n t a g e so f(a) CD4
+, (b) CD8
+,a n d(c) gδTCR
+ T cells in the splenic CD3
+ T-cell
population from susceptible congenic control (n = 26), Mcs5a-resistant congenic (n = 26), Mcs5a1 susceptible congenic (n = 20), and Mcs5a2
susceptible congenic (n = 15) rats. The significantly different (P < 0.05) gδTCR
+ T-cell population is indicated by an asterisk. Values are expressed
as average ± standard error of the mean. Mcs5a, resistant congenic harboring the mammary carcinoma susceptibility locus 5a resistance allele;
susc., susceptible congenic control; TCR, T-cell receptor.
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Page 7 of 13T cells from inguinal mammary LNs (Figure 6b). The
differential production of Th1 cytokines by susceptible
congenic control and Mcs5a-resistant congenic rats was
maintained after DMBA treatment (Figure 6a, b). The
conA-induced production of Th2 cytokines IL-4 (P =
0.61) and IL-6 (P = 0.27) and the Th17 cytokine IL-17
(P = 0.16) by splenic T cells was not significantly differ-
ent (Figure 6c). Interestingly, mitogen (conA)-induced
proliferation of different splenic T-cell subpopulations
was also significantly different in Mcs5a-resistant con-
genic rats as compared with susceptible congenic con-
trol rats. The percentage of daughter cells that had
undergone more than two divisions was significantly
higher in CD4
+ (P < 0.0001), CD8
+ (P < 0.0001), and
gδTCR
+ (P = 0.0009) T cells from Mcs5a-resistant con-
genic rats as compared with the susceptible congenic
control rats (Figure 6d). As a result, the percentage of
total T cells at the end of the proliferation experiment
Figure 4 Mcs5a increases the CD62L
high population among CD4
+,C D 8
+,a n dgδTCR
+ splenic T cells. (a) CD62L mean fluorescence
intensities (MFIs) of the splenic CD4
+, CD8
+, and gδTCR
+ T cells isolated from susceptible congenic control (open bars, n = 26) and Mcs5a-
resistant congenic (filled bars, n = 29) rats. Significantly different (P < 0.05) CD62L expression is indicated by an asterisk. (b) Examples of overlaid
flow cytometric histograms representing CD62L expression in CD4
+, CD8
+, and gδTCR
+ T cells in susceptible congenic control rats (dotted black
line) and Mcs5a-resistant congenic rats (solid black line). The grey dotted line and grey solid line represent fluorescence in the CD62L channel of
an isotype control antibody-stained (isotype) and unstained (no ab) cell sample, respectively. The black bar represents the gate used to quantify
the CD62L
high population in each T-cell subpopulation; the gate was set such that the MFI of the high population was fivefold that of the total
cells. (c) Percentage of CD62L
high-gated cells among CD4
+ splenic T cells. (d) Percentage of CD62L
high-gated cells among CD8
+ splenic T cells.
(e) Percentage of CD62L
high-gated cells among gδTCR
+ splenic T cells. CD62L
high-expressing T cells of susceptible congenic control (susc., n =
26), Mcs5a-resistant congenic (Mcs5a, n = 26), Mcs5a1 susceptible congenic (Mcs5a1, n = 20), and Mcs5a2 susceptible congenic (Mcs5a2, n = 15)
rat lines are shown. A significantly higher (P < 0.05) percentage of CD62L
high cells in the Mcs5a-resistant congenic line compared with the three
susceptible congenic lines is indicated by an asterisk. Values in (a, c-e) are expressed as average ± standard error of the mean. Mcs5a, mammary
carcinoma susceptibility locus 5a; TCR, T-cell receptor.
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Page 8 of 13Figure 5 Mcs5a is associated with an increased CD3
+ T-cell abundance attributable to increased gδTCR
+ T-cell abundance in the
mammary epithelium of DMBA-treated rats as compared with untreated rats. (a) Percentage of CD3
+, CD4
+, CD8
+,o rgδTCR
+ T cells of
total cells. Values are expressed as average ± standard error of the mean. Significantly higher (P < 0.05) percentages in the Mcs5a-resistant
congenic rat line (Mcs5a, filled bars; -DMBA n = 6, +DMBA n = 12) compared with the susceptible congenic control line (susc., open bars;
-DMBA n = 6, +DMBA n = 12) are indicated by an asterisk. Significantly higher (P < 0.05) percentage of T-cell abundance upon DMBA treatment
compared with no treatment is indicated by two asterisks. (b) Infiltrating T cells in frank mammary carcinomas of susceptible (open bars, n = 11)
and Mcs5a-resistant congenic rat line (filled bars, n = 12) rats. Significantly higher (P < 0.05) percentages in the Mcs5a-resistant congenic rat line
compared with the susceptible congenic control line are indicated by an asterisk. (c) Expression of CD4, CD8, and CD161a on gδTCR
+ T cells in
mammary gland and spleen of susceptible (open bars, n = 6) and Mcs5a-resistant congenic rat line (filled bars, n = 7) rats. DMBA, 7,12-
dimethylbenz(a)anthracene; Mcs5a, mammary carcinoma susceptibility locus 5a; TCR, T-cell receptor.
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Page 9 of 13was increased in the Mcs5a-resistant congenic samples
(Figure 6e).
We looked at the expression of markers CD25 and
CD134 in the T cells without or with conA stimulation.
The expression of CD25 was lower (P =0 . 0 2 )i nt h e
Mcs5a-resistant congenic animals after conA stimulation
(Figure S1A of Additional file 1). The expression of
CD134 was not different between susceptible and
Figure 6 Mcs5a allele is associated with increased concanavalin A (conA)-induced Th1 cytokine production and proliferation. (a)
Interleukin-2 (IL-2), interferon-gamma (IFNg), or tumor necrosis factor (TNF) concentrations (in picograms per milliliter) in the media produced by
cultured T cells from spleens of susceptible congenic control (susc., open bars; -DMBA n = 30, +DMBA n = 8) and Mcs5a congenic resistant
(Mcs5a, filled bars; -DMBA n = 30, +DMBA n = 8) rats without or with conA stimulation. (b) IL-2, IFNg, or TNF concentrations (in picograms per
milliliter) in the media produced by cultured T cells from inguinal mammary lymph nodes (LNs) of susceptible congenic control (open bars;
-DMBA n = 8, +DMBA n = 8) and Mcs5a congenic resistant (filled bars; -DMBA n = 8, +DMBA n = 8) rats without or with conA stimulation. (c)
IL-4, IL-6, or IL-17 concentrations (in picograms per milliliter) in the media produced by cultured T cells from spleens of susceptible congenic
control (open bars, n = 22) and Mcs5a congenic resistant (filled bars, n = 22) rats without or with conA stimulation. (d) Percentage of second-
and later-generation daughter cells among CD4
+, CD8
+, and gδTCR
+ T cells from susceptible congenic control (open bars, n = 24) and Mcs5a-
resistant congenic (filled bars, n = 26) rats without or with conA stimulation. Significantly different (P < 0.05) cytokine production or proliferation
between susceptible congenic control and Mcs5a-resistant congenic rat lines is indicated by an asterisk. Values are expressed as average ±
standard error of the mean. DMBA, 7,12-dimethylbenz(a)anthracene; Mcs5a, mammary carcinoma susceptibility locus 5a; TCR, T-cell receptor.
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t i o n a lf i l e1 ) .F i n a l l y ,w el o o k e da tt h er e d u c e dt h i o l
levels and mitochondrial membrane potential in the T
cells without or with conA stimulation. Both of these
parameters were significantly higher in the Mcs5a-resis-
tant congenic animals (P =0 . 0 0 7a n dP < 0.001) after
conA stimulation.
Discussion
MCS5A/Mcs5a is a non-protein-coding locus that associ-
ates with breast cancer risk in women and rats. Here, we
have shown that the resistant rat Mcs5a allele prevents
cancer induced by three distinctly acting mammary carci-
noma-inducing treatments, indicating that Mcs5a does not
control a specific initial step of mammary epithelial cell
transformation. In addition, formation of ISCs [15] was
not affected by Mcs5a, suggesting that Mcs5a acts during
early carcinoma progression. In the mammary gland trans-
plantation assay, it was demonstrated that Mcs5a acts in a
non-mammary cell-autonomous fashion. This, together
with the observation that Fbxo10 differential expression
manifests only in T cells [14], led to the hypothesis that
Mcs5a does not solely function in the mammary parench-
yma to modulate mammary cancer susceptibility but
instead acts through the immune system. To assess the
involvement of the immune system, we conducted a bone
marrow transplantation assay, in which we used irradia-
tion to eliminate the recipient rat bone marrow in order
to replace it with bone marrow cells from donor rats of
the same or opposite Mcs5a genotype. At the maximal
dose of radiation, only partial replacement could be
achieved as a higher dose of radiation resulted in ovarian
and mammary organ damage that compromised mam-
mary carcinoma development. At the maximal dose of
radiation, the mammary carcinoma multiplicities of the
control transplant groups S:S and R:R were approximately
twofold lower compared with the average DMBA-induced
mammary carcinoma multiplicity routinely obtained in
non-irradiated rats of the same genotypes (Figure 1a) and
this was due to radiation organ damage. Nevertheless, par-
tial replacement (average of greater than 50%) of the
immune cells of the Mcs5a-resistant congenic rats with
immune cells of the susceptible congenic control rats
(transplant group S:R) yielded a mammary carcinoma
multiplicity intermediate to the control transplant groups
R:R and S:S. This intermediate phenotype of partially
reconstituted rats is quantitatively comparable to the inter-
mediate mammary carcinoma multiplicity phenotype of
rats that are genetically heterozygous for the Mcs5a-resis-
tant allele [5]. We concluded that Mcs5a acts through
components of the immune system to modulate mammary
carcinoma multiplicity.
Specific T-cell phenotypes are also under control of
the synthetically interacting Mcs5a elements that control
Fbxo10 transcript levels and mammary carcinoma multi-
plicity. We found an overabundance of gδTCR
+ T cells
(important in mucosal cell surface surveillance), but not
CD4
+ (T helper) and CD8
+ (cytotoxic) T cells, in the
spleen of Mcs5a-resistant congenic rats compared with
susceptible congenic rats. In addition, the CD4
+,C D 8
+,
and gδTCR
+ T-cell populations harbored an increased
percentage of CD62L
high-expressing cells in Mcs5a-resis-
tant congenic rats. The resistant Mcs5a allele was also
found to be associated with an increased proliferation
rate of activated splenic T cells as well as the production
of the Th1 cytokines IL-2, IFNg, and TNF of activated T
cells from spleen and, to a greater extent, from inguinal
mammary LNs. The production of Th2 or Th17 cyto-
kines was not affected by Mcs5a. T cells from Mcs5a-
resistant congenic rats showed lower CD25 expression
(IL2Ra) but higher cellular reduced thiol levels and
mitochondrial membrane potential and increased IL-2
production. Considering these results, we propose that
higher proliferative response in Mcs5a-resistant con-
genic T cells could be due primarily to increased cyto-
kine signaling and lower oxidative stress.
Considering the altered T-cell homeostasis and func-
tionality associated with the resistant Mcs5a allele, we
speculate that T cells act at the mammary gland to control
mammary carcinoma susceptibility. To begin to explore
this hypothesis, we compared the T-cell population within
the mammary epithelium between the susceptible con-
genic control and the Mcs5a-resistant congenic rats. We
found a higher abundance of mammary epithelium-resid-
ing CD3
+ T cells, mainly consisting of gδTCR
+ T cells in
the DMBA-treated Mcs5a-resistant congenic rats. In con-
trast to the splenic gδTCR
+ T cells, most of the gδTCR
+ T
cells in the mammary gland are double-positive for CD4
a n dC D 8a n da l s oe x p r e s s e dN K - r e c e p t o rP 1C D 1 6 1 a.
This result suggests that the mammary gδTCR
+ Tc e l l s
may harbor increased cytotoxic characteristics that are
potentially capable of killing emerging tumor cells. In con-
trast to normal and carcinogen-exposed mammary gland,
frank mammary carcinomas have a low abundance of
gδTCR
+ T cells. The mammary carcinoma T-cell popula-
tion consists mainly of abTCR
+ Tc e l l s .T h i sr a i s e sa n
interesting possibility that immunoprevention of breast
cancer versus breast cancer therapy may need to focus on
different T-cell class targets, namely gδTCR
+ Tc e l l sf o r
prevention and abTCR
+ T cells for therapy.
Increased gδTCR
+ T-cell abundance in the mammary
epithelium is consistent with the observations that
Mcs5a-resistant congenic rats have an increased popula-
tion of CD62L
high-expressing T cells and that CD62L
(L-selectin) expression was highest in gδTCR
+ as com-
pared with CD4
+ and CD8
+ splenic T cells (Figure 4a).
L-selectin is a cell adhesion protein involved in leuko-
cyte-endothelial ‘rolling’ to facilitate extravasation of
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Page 11 of 13leukocytes from blood and lymphatic vessels and in
homing of leukocytes to secondary LNs and tumors in
extralymphoid organs [17-19].
Interestingly, gδTCR
+ T cells have been implicated in
the protection against breast cancer in women.
Decreased peripheral abundance of gδTCR
+ T cells and
their diminished IFNg production were recently shown
to be associated with breast cancer [20]. Treatment of
osteoporosis with bisphosphonates, compounds known
as gδTCR
+ T-cell agonists [21], has been associated with
reduced breast cancer risk [22]. Additionally, the Th1
cytokine IFNg was implicated in tumor immune surveil-
lance in mice [23].
Here, we have shown that the human-rat conserved
non-protein-coding MCS5A/Mcs5a locus acts in a non-
mammary cell-autonomous fashion through the immune
system and modifies the homeostasis and functions of T
cells. Each of these phenotypes or a combination of them
has the potential to underlie the mammary carcinoma
resistance phenotype mediated by the resistant Mcs5a
allele. Possible mechanisms include immune surveillance
or immune cell-produced Th1 cytokines altering the cellu-
lar composition/differentiation of the mammary parench-
yma or both. In the future, additional mechanistic studies
on the immunological aspect of Mcs5a will address the
contribution of each of the observed T-cell phenotypes to
Mcs5a-mediated mammary carcinoma resistance.
Conclusions
The non-protein-coding human-rat conserved mammary
carcinoma susceptibility locus Mcs5a modulates mam-
mary tumor multiplicity through a mechanism beyond the
initial stage of epithelial cell transformation, during early
cancer progression. Mcs5a acts in a non-mammary cell-
autonomous manner through the immune system. The
resistant allele is associated with an overabundance of
gδTCR
+ T cells in the spleen, an overabundance of
CD62L
high-expressing cells of all T-cell classes, and,
importantly, an overabundance of gδTCR
+ T cells (CD4
+,
CD8
+, and CD161a
+) in the mammary epithelium after
treatment with the carcinogen DMBA. gδTCR
+ T cells are
the most abundant T-cell class in the mammary epithe-
lium but not in mammary carcinomas. The resistant
Mcs5a allele is also associated with increased proliferation
and Th1, but not Th2 or Th17, cytokine secretion of acti-
vated T cells. We hypothesize that the resistant Mcs5a
allele acts through specific cells of the immune system to
prevent mammary carcinoma development.
Additional material
Additional file 1: Mcs5a and T-cell associations. Mcs5a is associated
with decreased conA-induced CD25 upregulation in T-cells (Figure S1).
Mcs5a is associated with activation induced changes in reduced thiol
levels and mitochondrial membrane potential T-cells (Figure S2).
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